Targeting old bottleneck reveals new anticancer drug strategy
Hot target SIRT2 regulates ribonucleotide reductase
The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists at Winship Cancer Institute of Emory University have identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts.
The results were published on July 19 in Nature Communications.
Ribonucleotide reductase controls the supply of DNA building blocks, which cancer cells need in abundance for fast growth. Cancer researchers have long had an interest in ribonucleotide reductase, which converts RNA components (ribonucleotides) into DNA building blocks. Several more traditional chemotherapy drugs, such as hydroxyurea, fludarabine, cladribine and gemcitabine, inhibit ribonucleotide reductase by a different mechanism.
Researchers led by Xingming Deng, MD, PhD, found that one of ribonucleotide reductase’s two parts (RRM2) is regulated by a tag, called acetylation, and identified another enzyme (Kat7) that adds that tag. Acetylation at a particular site inactivates RRM2 by preventing individual molecules of RRM2 from pairing up.
“Based on our findings, we will develop novel anticancer agents that inhibit ribonucleotide reductase activity by directly regulating RRM2 acetylation in cancer cells,” says Deng, who is professor of radiation oncology at Emory University School of Medicine and director of the discovery theme in the Discovery and Developmental Therapeutics research program at Winship.
In addition, Deng’s team observed that Sirt2, an enzyme that removes acetylation from RRM2 and activates it, is more abundant in samples from lung cancer patients. Sirt2 could be a prognostic biomarker for lung cancer, the authors suggest.
Sirt2 was a hot target for anti-cancer researchers already, but the Winship results provide new insights into how Sirt2 inhibitors preferentially affect cancer cells. Sirt2 has been difficult to develop inhibitors for, because it is part of a family (sirtuins) and many compounds hit more than one.
Sirt2 has other substrates besides RRM2, Deng notes. Also, RRM2 becomes deacetylated after DNA damage, so Sirt2 inhibitors could sensitize cancer cells to chemotherapy or radiation.
Co-authors include Emory biophysicist Kurt Warncke, PhD, and at Winship, David Yu, MD, PhD, Haian Fu, PhD, Suresh Ramalingam, MD and Walter Curran, MD. Paul Doetsch, PhD, previously at Emory and now at the National Institute of Environmental Health Sciences, contributed to the paper. First author Guo Chen, PhD, is now at Jinan University in China.
Research in Deng’s lab is supported by the National Cancer Institute (R01CA193828, R01CA136534, R01CA200905), by the Winship Fashion a Cure Research Scholar Award and the Endowed Chair for Cancer Biology (Radiation Oncology).
Related Journal Article